11630 SW 97 Street, Miami, Florida 33176, US
Advertising Driven Press Release Distribution
Advertising Driven Press Release Distribution
DelveInsight’s CAR T-Cell Therapy pipeline report gives extensive insights into the CAR T-Cell Therapy pipeline landscape, including 250+ companies and 250+ pipeline therapies. It includes clinical and nonclinical stage medicines in the pipeline medication profiles. It also examines medicines by product type, stage, administration route, and molecule type.
Some of the Crucial Highlights from the CAR T-Cell Therapy Pipeline Report
To learn more, request sample @ CAR T-Cell Therapy Clinical Trials
CAR T-Cell Therapy: Overview
CAR T-cells are fusion proteins made up of one or more T-cell receptor intracellular signalling domains with a single-chain fragment varying from a monoclonal antibody.
CAR T-Cell Therapy involves genetically modifying a patient’s autologous T-cells to express a CAR that recognises a tumour antigen, followed by ex vivo cell multiplication and re-infusion. CAR T-Cell Therapies are being used to treat malignancies of all kinds.
CAR T-Cell Therapy Pipeline Analysis: Drug Profiles
JWCAR029: JW Therapeutics
Product Description
JWCAR029 (Relmacabtagene autoleucel) is a CAR-T cell product that targets CD19 and is being developed as a third-line treatment for relapsed or refractory (r/r) B-cell lymphoma.
Phase II
NCT04089215: In June 2019, a phase II, open-label, single-arm, multicenter research in China was launched to assess the efficacy and safety of JWCAR029 in adult R/R Non-Hodgkin’s Lymphoma patients. This is a multicenter, phase II, open-label, single-arm research in adult individuals with R/R Non-Hodgkin’s Lymphoma in China to assess the safety, effectiveness, pharmacokinetics (PK), and pharmacodynamics (PD) of JWCAR029.
Get in touch to know more about the CART T-Cell Therapy FDA Approval
CAR T-Cell Therapy Pipeline Therapies and Key Companies
CAR T-Cell Therapy Therapeutics Assessment
Coverage: Global
CAR T-Cell Therapy Key Players: Bluebird Bio, Cartesian Therapeutics, Autolus Limited, Novartis, BioAtla, JW Therapeutics, among others
CAR T-Cell Therapy Pipeline Therapies: bb21217, Descartes-08, AUTO4, CTL119, BA 3011, WCAR029, and others
Table of Contents
| 1. | Key Insights |
| 2. | Report Introduction |
| 3. | CAR T-Cell Therapy: Snapshot |
| 4. | CAR T-Cell Therapy: Overview |
| 5. | CAR T-Cell Therapy Pipeline Scenario |
| 6. | CAR T-Cell Therapy Pipeline Therapeutics |
| 7. | CAR T-Cell Therapy Late Stage Products (Registered) |
| 8. | CAR T-Cell Therapy Late Stage Products (Pre-registration) |
| 9. | CAR T-Cell Therapy Mid Stage Products (Phase II) |
| 10. | CAR T-Cell Therapy Early Stage Products (Phase I/II) |
| 11. | CAR T-Cell Therapy Early Stage Products (Phase I) |
| 12. | CAR T-Cell Therapy IND-stage Products |
| 13. | CAR T-Cell Therapy Preclinical stage Products |
| 14. | CAR T-Cell Therapy Discovery stage Products |
| 15. | CAR T-Cell Therapy Therapeutic Assessment |
| 16. | CAR T-Cell Therapy Inactive Products |
| 17. | CAR T-Cell Therapy- Unmet Needs |
| 18. | CAR T-Cell Therapy- Market Drivers and Barriers |
| 19. | Appendix |
| 20. | About DelveInsight |
Know more what’s covered in the CAR T-Cell Therapy Assessment Report
Key Questions Answered in the CAR T-Cell Therapy Pipeline Report
Related Reports
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Insights
Get a comprehensive analysis of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline therapies and key companies including Autolus, PersonGen Biotherapeutics, Pepromene Bio, Inc., Actinium Pharmaceuticals, among others.
CAR T-Cell Therapy for Multiple Myeloma Pipeline Insights
Get a comprehensive analysis of CAR T-Cell Therapy for Multiple Myeloma pipeline therapies and key companies including Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation, among others.
CAR T Related Neurotoxicity Pipeline Insights
“CART related Neurotoxicity (NT) Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the CART related Neurotoxicity (NT) market.
CAR T-Cell Therapy for Non Hodgkin’s Lymphoma Pipeline Insights
Get comprehensive analysis of CAR T-Cell Therapy for Non Hodgkin’s Lymphoma pipeline therapies and key companies including Juno Therapeutics, Caribou Biosciences, Allogene Therapeutics, among others.
Neo Antigen T Cell Therapy Pipeline Insights
“Neo Antigen T-Cell Therapy Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenarios and growth prospects across the Neo Antigen T-Cell Therapy market.
T Cell Therapy Pipeline Insights
“T Cell Therapy Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenarios and growth prospects across the T Cell Therapy market.
Lymphatic Malformations Pipeline Insights
Get comprehensive analysis of Lymphatic Malformations pipeline therapies and key companies including Vanthera, Cerecor, Inc., Protara therapeutics, among others.
Necrobiosis Lipoidica Pipeline Insights
Get comprehensive analysis of Necrobiosis Lipoidica pipeline therapies and key companies including Novartis, Processa Pharmaceuticals, among others.
Recurrent Malignant Glioma Pipeline Insights
“Recurrent Malignant Glioma Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenarios and growth prospects across the Recurrent Malignant Glioma market.
Gliosarcoma Pipeline Insights
“Gliosarcoma Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenarios and growth prospects across the Gliosarcoma market.
Related Posts
CAR T-Cell Therapy Market for Non Hodgkin Lymphoma
Chimeric Antigen Receptor Therapies in Blood Cancers
CAR T-Cell Therapy Market in Acute Lymphoblastic Leukemia
Get in touch with our Business executive @ CAR T-Cell Therapy Pipeline Insights to know more
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Sandeep Joshi
info@delveinsight.com
+1(919)321-6187
Connect With Us at:
For exclusive content regarding the latest trends in the world of Press Release distribution.
